Literature DB >> 3118800

Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis.

A B Schryvers1, J Ogunariwo, S Chamberland, A J Godfrey, H R Rabin, L E Bryan.   

Abstract

Beta-lactam resistance in Pseudomonas aeruginosa detected only during ceftazidime therapy of cystic fibrosis patients was studied. Evaluation of resistant and susceptible isolates from one patient and resistant laboratory derivatives indicated that elevated beta-lactamase levels were the primary determinant of resistance. Susceptible isolates outgrew resistant isolates on antibiotic-free medium.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3118800      PMCID： PMC174959          DOI： 10.1128/AAC.31.9.1438

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Detection of beta-lactamase production by gram-negative bacteria.

Authors:  G Masuda; S Tomioka; M Hasegawa
Journal:  J Antibiot (Tokyo)       Date:  1976-06       Impact factor: 2.649

2.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

Review 3.  Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.

Authors:  C C Sanders; W E Sanders
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

4.  Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas.

Authors:  J L Blumer; R C Stern; J D Klinger; T S Yamashita; C M Meyers; A Blum; M D Reed
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

5.  Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis.

Authors:  J A Hoogkamp-Korstanje; J van der Laag
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

6.  Transferable drug resistance in Pseudomonas aeruginosa.

Authors:  L E Bryan; H M Van Den Elzen; J T Tseng
Journal:  Antimicrob Agents Chemother       Date:  1972-01       Impact factor: 5.191

7.  Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.

Authors:  R Gold; A Overmeyer; B Knie; P C Fleming; H Levison
Journal:  Pediatr Infect Dis       Date:  1985 Mar-Apr

8.  Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections.

Authors:  M J Gribble; A W Chow; S C Naiman; J A Smith; W R Bowie; S L Sacks; L Grossman; N Buskard; G H Growe; L H Plenderleith
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191
  8 in total
  3 in total

1.  In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor.

Authors:  K Nishida; C Kunugita; T Uji; F Higashitani; A Hyodo; N Unemi; S N Maiti; O A Phillips; P Spevak; K P Atchison; S M Salama; H Atwal; R G Micetich
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Marked phenotypic variability in Pseudomonas cepacia isolated from a patient with cystic fibrosis.

Authors:  G Y Larsen; T L Stull; J L Burns
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

3.  Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection.

Authors:  Sharif M Abdelghany; Derek J Quinn; Rebecca J Ingram; Brendan F Gilmore; Ryan F Donnelly; Clifford C Taggart; Christopher J Scott
Journal:  Int J Nanomedicine       Date:  2012-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.